Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis

Fig. 3

a VS and b median CD4+ CFB at Week 48 with DTG versus comparators. FE model. *Indicates treatment comparisons are significantly different. ATV/r, ritonavir-boosted atazanavir; BIC, bictegravir; CFB, change from baseline; Crl, credible interval; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; EVG/c, cobicistat-boosted elvitegravir; FE, fixed effect; INSTIs, Integrase strand inhibitors; LPV/r, lopinavir-boosted ritonavir; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; OR, odds ratio; PIs, protease inhibitors; RAL, raltegravir; RPV, rilpivirine; VS, virologic suppression

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us